Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Ras; rho guanine nucleotide exchange factors (ARHGEFs; GEFs)

An in vitro study suggests prolonged inhibition of interactions between Ras and GEFs could help treat cancer. Oncogenic mutations in Ras fix the protein in an active, GTP-bound conformation. In multiple cancer cell lines, prolonged treatment with andrographolide (AGP), a compound that is predicted to block Ras-GEF interaction, inhibited GTP loading, oncogenic Ras signaling and cell growth. Next steps include optimizing AGP derivatives for potency and in vivo application.

SciBX 6(26); doi:10.1038/scibx.2013.650
Published online July 11, 2013

Patent and licensing status undisclosed

Hocker, H.J. et al. Proc. Natl. Acad. Sci. USA; published online June 4, 2013;
doi:10.1073/pnas.1300016110
Contact: Alemayehu A. Gorfe, The University of Texas Health Science Center at Houston, Houston, Texas
e-mail:
alemayehu.g.abebe@uth.tmc.edu

Contact: John F. Hancock, same affiliation as above
e-mail:
john.f.hancock@uth.tmc.edu

Contact: Johnson Stanslas, University Putra Malaysia, Selangor, Malaysia
e-mail:
jstanslas@yahoo.co.uk